Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis
21 Mar, 2023 | 13:23h | UTCTwo Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Largest study to date of lebrikizumab supports its use for treatment of atopic dermatitis – George Washington University
Commentary: Lebrikizumab Effective for Adults, Teens With Atopic Dermatitis – HealthDay